|
Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast Clinical research trials and Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast. Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast  Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast
Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast
For Condition: recurrent breast cancer,stage 4 breast cancer,inflammatory breast cancer,stage 3A breast cancer,stage 3B breast cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , UNC Lineberger Comprehensive Cancer Center
Synopsis: RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy with radiation therapy may be an effective treatment for breast cancer. PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab and radiation therapy in treating women who have stage III or stage IV invasive primary cancer of the breast.
Details: OBJECTIVES: I. Determine the tolerability of trastuzumab (Herceptin) and radiotherapy in women with stage III or IV invasive primary carcinoma of the breast that continues to overexpress HER2 following neoadjuvant systemic chemotherapy. II. Determine the pathologic response rate, locoregional recurrence rate, and time to locoregional recurrence in patients treated with this regimen who did not achieve clinical complete remission following neoadjuvant systemic chemotherapy. PROTOCOL OUTLINE: Patients who received trastuzumab (Herceptin) in combination with prior neoadjuvant chemotherapy receive trastuzumab IV over 30 minutes on day 1, followed by radiotherapy on days 1-5. Patients who did not receive trastuzumab in combination with prior neoadjuvant chemotherapy receive a loading dose of trastuzumab IV over 90 minutes, followed one week later by trastuzumab IV over 30 minutes on day 1, followed by radiotherapy on days 1-5. Radiotherapy begins within 3-4 weeks after completion of neoadjuvant chemotherapy. Treatment continues weekly for 5 courses in the absence of unacceptable toxicity. Patients are followed at 3 weeks for surgical resectability, then every 3 months for 2 years, and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven invasive primary carcinoma of the breast by fine needle aspiration cytology, core needle biopsy, or incisional biopsy; No prior excisional biopsy - Stage III or IV disease, including the following: Any T with N2 or N3; Inflammatory breast cancer or otherwise inoperable T4; Supraclavicular/infraclavicular adenopathy; Distant metastasis with measurable disease in the breast or lymph nodes - Must have received neoadjuvant systemic chemotherapy with or without trastuzumab (Herceptin) within the past 4 weeks and have residual tumor that continues to overexpress HER2 - Measurable or evaluable locoregional disease after completion of neoadjuvant chemotherapy - Synchronous bilateral primary carcinoma of the breast allowed if the more serious of the 2 carcinomas meets the above staging criteria - Candidate for locoregional therapy consisting of radiotherapy followed by surgery - Hormone receptor status: Not specified --Prior/Concurrent Therapy-- - Biologic therapy: See Disease Characteristics - Chemotherapy: See Disease Characteristics - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics; No prior radiotherapy to breast or regional lymph nodes - Surgery: See Disease Characteristics --Patient Characteristics-- - Age: Over 18 - Sex: Female - Menopausal status: Any status - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: WBC greater than 3,000/mm3; Platelet count greater than 100,000/mm3; Hemoglobin greater than 12 g/dL - Hepatic: Not specified - Renal: Not specified - Cardiovascular: Left ventricular ejection fraction normal by radionuclide ventriculography - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception
Total Enrollment:
Location and Contact Information:
Overall Study Official:
CarolynSartor, Study Chair, UNC Lineberger Comprehensive Cancer Center
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
United States
Additional Information:
Study ID Numbers: CDR0000068120; UNC-9925,NCI-G00-1835
Study Start Date: March 2000
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006109
Other Inflammatory Breast Cancer Studies:
1. Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
2. Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
3. Drug Resistance Inhibition in Treating Patients With Recurrent or Metastatic Breast Cancer
4. Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
5. Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
Related Studies:
Other inflammatory breast cancer Clinical Trials
Other North Carolina Clinical Trials
Other Chapel Hill Clinical Trials
Trastuzumab and Radiation Therapy in Treating Women With Stage III or Stage IV Invasive Primary Cancer of the Breast
|
|
|
|
|
|
|
|
